Genedrive PLC Result of AGM (5862Q)
November 30 2016 - 8:16AM
UK Regulatory
TIDMGDR
RNS Number : 5862Q
Genedrive PLC
30 November 2016
RNS
For release: 30 November 2016
genedrive plc ("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics
company, announces that at the Annual General Meeting, held in
Manchester today, all resolutions proposed were duly passed.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Peel Hunt LLP
James Steel
+44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF test have been
launched in India and a Genedrive(R) HCV test has been successfully
assessed by the Institut Pasteur, Paris.
genedrive plc was formerly Epistem plc and continues to provide
contract research services to drug development companies under the
Epistem brand name.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBSBDBSBXBGLG
(END) Dow Jones Newswires
November 30, 2016 09:16 ET (14:16 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024